Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS-CoV-2 vaccine candidates in the Syrian hamster model
Open accessAbstract
The availability of a safe and effective vaccine would be the eventual measure to deal with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) threat. Here, we have assessed the immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidates BBV152A, BBV152B, and BBV152C in Syrian hamsters. Three dose vaccination regimes with vaccine candidates induced significant titers of SARS-CoV-2-specific IgG and neutralizing antibodies. BBV152A and BBV152B vaccine candidates remarkably generated a quick and robust immune response. Post-SARS-CoV-2 infection, vaccinated hamsters did not show any histopathological changes in the lungs. The protection of the hamster was evident by the rapid clearance of the virus from lower respiratory tract, reduced virus load in upper respiratory tract, absence of lung pathology, and robust humoral immune response. These findings confirm the immunogenic potential of the vaccine candidates and further protection of hamsters challenged with SARS-CoV-2. Of the three candidates, BBV152A showed the better response.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Inactivated SARS-CoV-2 vaccine candidates have shown promising results in preclinical trials.
“Inactivated SARS-CoV-2 vaccine candidates have shown promising results in preclinical trials.13, 14, 15”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
No citation lists for this paper
No citation lists for this paper yet — checked again daily.
References 32 · Cited by 74
Research works printed but not linked: 26
- Addetia A. Crawford K.H. Dingens A. Zhu H. Roychoudhury P. Huang M.L. Jerome K.R. Bloom J.D. Greninger A.L. Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate J. Clin. Microbiol. 58 2020 e02107 e02120 10.1128/JCM.02107-20 32826322 PMC7587101 · DOI · Paper page
- Chan J.F. Zhang A.J. Yuan S. Poon V.K. Chan C.C. Lee A.C. Chan W.M. Fan Z. Tsoi H.W. Wen L. Liang R. Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility Clin. Infect. Dis. Mar. 26 2020 ciaa325 PMC7184405 32215622
- Clements J.D. Freytag L.C. Parenteral vaccination can be an effective means of inducing protective mucosal responses Clin. Vaccin. Immunol. 23 2016 438 441 PMC4895008 27122485
- Docea A.O. Tsatsakis A. Albulescu D. Cristea O. Zlatian O. Vinceti M. Moschos S.A. Tsoukalas D. Goumenou M. Drakoulis N. Dumanov J.M. A new threat from an old enemy: Re-emergence of coronavirus Int. J. Mol. Med. 45 2020 1631 1643 32236624 PMC7169834
- Ganneru B. Jogdand H. Dharam V.K. Molugu N.R. Prasad S.D. Vellimudu S. Ella K.M. Ravikrishnan R. Awasthi A. Jose J. Rao P. Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion Inactivated SARS-CoV-2 Vaccine-Bbv152 2020 bioRxiv 10.1101/2020.09.09.285445 · DOI
- Goumenou M. Sarigiannis D. Tsatsakis A. Anesti O. Docea A.O. Petrakis D. Tsoukalas D. Kostoff R. Rakitskii V. Spandidos D.A. Aschner M. COVID-19 in Northern Italy: an integrative overview of factors possibly influencing the sharp increase of the outbreak Mol. Med. Rep. 22 2020 20 32 32319647 PMC7248465
- Holmgren J. Czerkinsky C. Mucosal immunity and vaccines Nat. Med. 11 2005 S45 S53 15812489
- Imai M. Iwatsuki-Horimoto K. Hatta M. Loeber S. Halfmann P.J. Nakajima N. Watanabe T. Ujie M. Takahashi K. Ito M. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development Proc. Natl. Acad. Sci. 117 2020 16587 16595 32571934 PMC7368255
- Islam M.T. Nasiruddin M. Khan I.N. Mishra S.K. Kudrat-E-Zahan M. Riaz T.A. Ali E.S. Rahman M.S. Mubarak M.S. Martorell M. Cho W.C. A perspective on emerging therapeutic interventions for COVID-19 Front. Public Health 8 2020 281 32733837 PMC7362761
- Li Q. Guan X. Wu P. Wang X. Zhou L. Tong Y. Ren R. Leung K.S.M. Lau E.H.Y. Wong J.Y. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia N. Engl. J. Med. 382 2020 1199 1207 31995857 PMC7121484
- Luan J. Lu Y. Jin X. Zhang L. Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection Biochem. Biophys. Res. Commun. 526 2020 165 169 32201080 PMC7102515
- Lv Z. Deng Y.Q. Ye Q. Cao L. Sun C.Y. Fan C. Huang W. Sun S. Sun Y. Zhu L. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody Science 369 2020 1505 1509 32703908 PMC7402622
- Mohandas S. Jain R. Yadav P.D. Shete-Aich A. Sarkale P. Kadam M. Kumar A. Deshpande G. Baradkar S. Patil S. Evaluation of the susceptibility of mice & hamsters to SARS-CoV-2 infection Indian J. Med. Res. 151 2020 479 32611917 PMC7530454
- Pandey S.C. Pande V. Sati D. Upreti S. Samant M. Vaccination strategies to combat novel corona virus SARS-CoV-2 Life Sci. 256 2020 117956 32535078 PMC7289747
- Phan L.T. Nguyen T.V. Luong Q.C. Nguyen T.V. Nguyen H.T. Le H.Q. Nguyen T.T. Cao T.M. Pham Q.D. Importation and human-to-human transmission of a novel coronavirus in Vietnam N. Engl. J. Med. 382 2020 872 874 31991079 PMC7121428
- Reynolds H.Y. Immunoglobulin G and its function in the human respiratory tract Mayo Clinic Proc. 63 1988 161 174 3276975
- Roberts A. Vogel L. Guarner J. Hayes N. Murphy B. Saki S. Subbarao K. Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters J.Virol. 79 2005 503 511 15596843 PMC538722
- Sanders B. Koldijk M. Schuitemaker H. Inactivated viral vaccines Vaccine Analysis: Strategies, Principles, and Control 2015 Springer 45 80
- Sia S.F. Yan L.M. Chin A.W. Fung K. Choy K.T. Wong A.Y. Kaewpreedee P. Perera R.A. Poon L.L. Nicholls J.M. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters Nature 583 2020 834 838 32408338 PMC7394720
- Tostanoski L.H. Wegmann F. Martinot A.J. Loos C. McMahan K. Mercado N.B. Yu J. Chan C.N. Bondoc S. Starke C.E. Nekorchuk M. Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters Nat. Med 26 2020 1694 1700 32884153 PMC7671939
- Tsatsakis A. Calina D. Falzone L. Petrakis D. Mitrut R. Siokas V. Pennisi M. Lanza G. Libra M. Doukas S.G. Doukas P.G. SARS-CoV-2 pathophysiology and its clinical implications: an integrative overview of the pharmacotherapeutic management of COVID-19 Food Chem. Toxicol. 146 2020 111769 32979398 PMC7833750
- van Doremalen N. Lambe T. Spencer A. Belij-Rammerstorfer S. Purushotham J.N. Port J.R. Avanzato V.A. Bushmaker T. Flaxman A. Ulaszewska M. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques Nature 586 2020 578 582 32731258 PMC8436420
- Wang Y. Miao J. Chard L. Wang Z. Syrian hamster as an animal model for the study on infectious diseases Front. Immunol. 10 2019 2329 31632404 PMC6781508
- Wilder-Smith A. Chiew C.J. Lee V.J. Can we contain the COVID-19 outbreak with the same measures as for SARS? Lancet Infect. Dis. 20 2020 E102 E105 32145768 PMC7102636
- Yadav P. Ella R. Kumar S. Patil D. Mohandas S. Shete A. Bhati G. Sapkal G. Kaushal H. Patil S. Remarkable immunogenicity and protective efficacy of BBV152, an inactivated SARS-CoV-2 vaccine in rhesus macaques Res. Square 2020 10.21203/rs.3.rs-65715/v1 · DOI
- Yu J. Tostanoski L.H. Peter L. Mercado N.B. McMahan K. Mahrokhian S.H. Nkolola J.P. Liu J. Li Z. Chandrashekar A. Martinez D.R. DNA vaccine protection against SARS-CoV-2 in rhesus macaques Science 369 2020 806 811 32434945 PMC7243363
- Authors
- Mohandas, S., Yadav, P. D., Shete-Aich, A., Abraham, P., Vadrevu, K. M., Sapkal, G., Mote, C., Nyayanit, D., Gupta, N., Srinivas, V. K., Kadam, M., Kumar, A., Majumdar, T., Jain, R., Deshpande, G., Patil, S., Sarkale, P., Patil, D., Ella, R., Prasad, S. D., Sharma, S., Ella, K. M., Panda, S., & Bhargava, B.
- Affiliations
- ICMR-National Institute of Virology (IN)
- Bharat Biotech (India) (IN)
- Krantisinh Nana Patil College of Veterinary Science (IN)
- Indian Council of Medical Research (IN)
- Corresponding author
- Yadav, Pragya D.
- ORCID
- Mohandas, Sreelekshmy
- Yadav, Pragya D.
- Abraham, Priya
- Vadrevu, Krishna Mohan
- Sapkal, Gajanan
- Mote, Chandrashekhar
- Nyayanit, Dimpal
- Gupta, Nivedita
- Kadam, Manoj
- Kumar, Abhimanyu
- Majumdar, Triparna
- Jain, Rajlaxmi
- Deshpande, Gururaj
- Patil, Savita
- Sarkale, Prasad
- Patil, Deepak
- Ella, Raches
- Prasad, Sai D.
- Ella, Krishna M.
- Panda, Samiran
- Bhargava, Balram
- Venue
- iScience
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 24
- Issue
- 2
- Pages
- 102054
- ISSN
- 2589-0042 (ISSN-L)
- PMC
- PMC7829205
- OpenAlex
- W3117298803
- Cited by
- 74
- References
- 32
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 6 · 2023: 7 · 2022: 18 · 2021: 41
- FWCI
- 5.70
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- iScience (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Indian Council of Medical Research
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- BBV152, inactivated SARS-CoV-2 vaccine, COVID-19 vaccines, immunogenicity, protective efficacy, Syrian hamster model, neutralizing antibodies, humoral immune response, viral load clearance, lung pathology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
